I
Immuto Scientific
Structure-based therapeutics discovery company pioneering a novel class of tumor-specific drug targets
About Immuto Scientific
ImmuToScientific is a biotechnology startup that operates in the pharmaceutical industry, specifically in the field of drug discovery. The company has developed a proprietary platform that enables the detailed analysis of protein structures, dynamics, and interactions. This technology allows for the empirical derivation of native-state structures at an amino acid resolution for any protein or peptide, whether standalone or in a complex. This process is completed in a matter of weeks, providing a risk-free and efficient solution for pharmaceutical companies and researchers.
The company's primary clients are pharmaceutical companies and research institutions that are involved in drug discovery and development. By providing a more efficient and detailed analysis of protein structures, ImmuToScientific helps these clients to better understand their target's structure, function, and dynamics, which in turn aids in the development of more effective drugs.
ImmuToScientific's business model revolves around its proprietary platform, PLIMB. PLIMB provides high-resolution data on antibody binding, which eliminates other costly inefficiencies in the drug discovery process. This allows developers to focus on multiple high-probability leads simultaneously, saving both time and resources.
The company generates revenue by offering its services to pharmaceutical companies and research institutions. By offering a faster, more efficient method for analyzing protein structures, ImmuToScientific provides a valuable service that can potentially save its clients significant amounts of time and money in the drug discovery process.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Madworks Seed Accelerator
National Institutes of Health
Center for Technology Commercialization
DYDX Capital
WARF Ventures
Great Oaks Venture Capital
Gravity Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immuto Scientific on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immuto Scientific on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.